AbbVie press release (ABBV): Q3 Non-GAAP EPS of $3.82 beats by $0.05. – Revenue of $17.4B (+10.3% Y/Y) beats by $50M. – – Third-Quarter Global Net Revenues from the Immunology Portfolio Were $9.165 Billion, an Increase of 16.3 Percent on a Reported Basis, or 16.6 Percent
Abbvie Non-gaap EPS of $3.82 Beats by $0.05, Revenue of $17.4b Beats by $50M, Raises FY Guidance
AbbVie press release (ABBV): Q3 Non-GAAP EPS of $3.82 beats by $0.05. - Revenue of $17.4B (+10.3% Y/Y) beats by $50M. - - Third-Quarter Global Net Revenues from the Immunology Portfolio Were $9.165 Billion, an Increase of 16.3 Percent on a Reported Basis, or 16.6 Percent